Abstract
The purpose of this mini-review is to summarize and highlight the different advances in our understanding of the antimicrobial and antiangiogenic activity of squalamine, a cationic steroid isolated in 1993 from the dogfish shark Squalus Acanthias. Indeed, squalamine has shown to be useful for the treatment of important diseases such as cancers (lung, ovarian, brain and others), age-related macular degeneration (AMD) and the control of body weight in man. All these results led to a question: could we consider squalamine as a polyvalent drug of the future?
Keywords: squalamine, aminosterol, cancer, age-related macular degeneration (amd), appetite suppression, weight reduction
Current Cancer Drug Targets
Title: Squalamine: A Polyvalent Drug of the Future?
Volume: 5 Issue: 4
Author(s): Jean Michel Brunel, Chanaz Salmi, Celine Loncle, Nicolas Vidal and Yves Letourneux
Affiliation:
Keywords: squalamine, aminosterol, cancer, age-related macular degeneration (amd), appetite suppression, weight reduction
Abstract: The purpose of this mini-review is to summarize and highlight the different advances in our understanding of the antimicrobial and antiangiogenic activity of squalamine, a cationic steroid isolated in 1993 from the dogfish shark Squalus Acanthias. Indeed, squalamine has shown to be useful for the treatment of important diseases such as cancers (lung, ovarian, brain and others), age-related macular degeneration (AMD) and the control of body weight in man. All these results led to a question: could we consider squalamine as a polyvalent drug of the future?
Export Options
About this article
Cite this article as:
Brunel Michel Jean, Salmi Chanaz, Loncle Celine, Vidal Nicolas and Letourneux Yves, Squalamine: A Polyvalent Drug of the Future?, Current Cancer Drug Targets 2005; 5 (4) . https://dx.doi.org/10.2174/1568009054064642
DOI https://dx.doi.org/10.2174/1568009054064642 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Next Generation Tyrosine Kinase Inhibitor (TKI): Afatinib
Recent Patents on Anti-Cancer Drug Discovery Radiolabeled Protein-inhibitor Peptides with Rapid Clinical Translation towards Imaging and Therapy
Current Medicinal Chemistry Editorial (Hot Topic: Achieving Current Goals in Prevention and Treatment of Vascular Disease: An Update)
Current Pharmaceutical Design Carbazole Derivatives as Kinase-Targeting Inhibitors for Cancer Treatment
Mini-Reviews in Medicinal Chemistry Preface [Hot topic: Apoptosis and Cancer Therapeutics (Guest Editor: M. Saeed Sheikh)]
Current Cancer Drug Targets Receptor-based 3D-QSAR in Drug Design: Methods and Applications in Kinase Studies
Current Topics in Medicinal Chemistry Preclinical Evidence on the Anticancer Properties of Food Peptides
Protein & Peptide Letters PET-Evaluated Transport of [11C]Hydroxyurea Across the Rat Blood-Brain Barrier - Lack of Influence of Cyclosporin and Probenecid
Drug Metabolism Letters ImmunoPET in Neoplasms of Gastrointestinal Tract, Liver and Pancreas in the XXIst Century: Bridging the Gap Between Diagnosis and Therapy
Reviews on Recent Clinical Trials Multiple Sclerosis: Current and Future Treatment Options
Endocrine, Metabolic & Immune Disorders - Drug Targets New Chitosan Nanospheres for the Delivery of 5-Fluorouracil: Preparation, Characterization and in vitro Studies
Current Drug Delivery Prospects of miRNA-Based Therapy for Pancreatic Cancer
Current Drug Targets Evaluating Gene Delivery Using N-triethyl Chitosan Nanoparticles to AsPC-1 Cells and Predicting the Relation between Transfection, Cytotoxicity and Charge Ratio of Nanoparticles Via Mathematical Models
Drug Delivery Letters Epigenetics in Metastatic Breast Cancer: Its Regulation and Implications in Diagnosis, Prognosis and Therapeutics
Current Cancer Drug Targets Evaluation of the in vivo Safety Profiles of Rictor Inhibition Using a Zebrafish Model
Current Pharmaceutical Design Therapeutic Nanotechnology for Bone Infection Treatment – State of the Art
Current Drug Delivery Post-Translational Modifications of Nuclear Co-repressor RIP140: A Therapeutic Target for Metabolic Diseases
Current Medicinal Chemistry Betulinic Acid Derivatives as Anticancer Agents: Structure Activity Relationship
Anti-Cancer Agents in Medicinal Chemistry Tea (Camellia sinensis (L.)): A Putative Anticancer Agent in Bladder Carcinoma?
Anti-Cancer Agents in Medicinal Chemistry Peptide Receptor Radionuclide Therapy with Somatostatin Analogues in Neuroendocrine Tumors
Anti-Cancer Agents in Medicinal Chemistry